Trials / Completed
CompletedNCT00376324
Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone
An Open-Label, Multiple-Dose Study of the Pharmacokinetics of Tigecycline in Human Bone
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Study to examine the concentration of the study drug, tigecycline, in human bone samples following the administration of multiple doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tigecycline | Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals. |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2006-09-14
- Last updated
- 2009-07-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00376324. Inclusion in this directory is not an endorsement.